BidaskClub upgraded shares of Akebia Therapeutics (NASDAQ:AKBA) from a strong sell rating to a sell rating in a research note released on Tuesday, BidAskClub reports.

A number of other brokerages have also commented on AKBA. Zacks Investment Research upgraded shares of Akebia Therapeutics from a sell rating to a hold rating in a research note on Friday, July 12th. Mizuho set a $16.00 price target on shares of Akebia Therapeutics and gave the company a buy rating in a research note on Friday, August 9th. HC Wainwright reduced their target price on shares of Akebia Therapeutics from $19.00 to $17.00 and set a buy rating for the company in a research note on Tuesday, August 6th. ValuEngine upgraded shares of Akebia Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. Finally, JPMorgan Chase & Co. assumed coverage on shares of Akebia Therapeutics in a research note on Thursday, May 2nd. They issued an overweight rating and a $12.00 target price for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $11.88.

Shares of AKBA stock opened at $4.70 on Tuesday. The firm has a market capitalization of $558.66 million, a PE ratio of -1.93 and a beta of 1.43. The firm has a fifty day simple moving average of $4.19 and a two-hundred day simple moving average of $5.78. The company has a current ratio of 1.70, a quick ratio of 1.15 and a debt-to-equity ratio of 0.06. Akebia Therapeutics has a 12 month low of $3.50 and a 12 month high of $10.45.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.05. The business had revenue of $100.80 million during the quarter, compared to analyst estimates of $88.35 million. Akebia Therapeutics had a negative net margin of 75.64% and a negative return on equity of 36.92%. On average, equities analysts predict that Akebia Therapeutics will post -1.41 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Aperio Group LLC bought a new stake in shares of Akebia Therapeutics in the 2nd quarter worth $31,000. First Quadrant L P CA bought a new stake in shares of Akebia Therapeutics in the 1st quarter worth $43,000. Wedbush Securities Inc. bought a new stake in shares of Akebia Therapeutics in the 2nd quarter worth $52,000. Advisor Group Inc. grew its stake in shares of Akebia Therapeutics by 3,206.3% in the 4th quarter. Advisor Group Inc. now owns 9,919 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 9,619 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Akebia Therapeutics in the 2nd quarter worth $54,000. Hedge funds and other institutional investors own 70.64% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.

Recommended Story: Rule of 72

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.